Pfizer and UCSB Collaborate on Major Diabeter Research Program

In partnership with UC Santa Barbara’s Institute for Collaborative Biotechnologies, Pfizer, the world’s largest research-based biomedical and pharmaceutical company, launched the Insulin Resistance Pathways Project (IRP). The three-year, $14 million investigation will focus on discovering new drugs to treat diabetes. The project is lead by Dr. Preston Hensley, Senior Director of Pfizer’s Worldwide Exploratory Science & Technology division.